John Simmons

Company: Natera

Job title: Global Vice President - Biopharma

Seminars:

How Signatera MRD testing is Transforming Cancer Care and Drug Development 8:50 am

The Signatera ctDNA MRD assay is shifting the paradigm of cancer management; ~40% of US oncologists ordered Signatera in Q1 2024 and to-date, over 175,000 real-world patients have been tested across 700,000+ longitudinal timepoints Increasingly, Signatera is being integrated into the physician-patient shared decision-making model across tumor types and practice settings Among 20+ studies prospectively…Read more

day: Day Two AM